9PDAurora-B mediated snail phosphorylation is essential for mitotic spindle checkpoint and for preventing chromosomal instability in breast cancer
Conclusions1. Snail is required for mitotic spindle checkpoint activation; 2. Snail is phosphorylated by Aurora B in mitosis; 3. Aurora-B medicated Snail phosphorylation is required for optinal activation of the spindle checkpoint and prevention of chromosomal instability in breast cancer.Legal entity responsible for the studyThe authors.FundingTianjin Medical University Cancer Institute and Hospital.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1584PExploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
ConclusionsThe identified IGS was able to select APNSCLC pts with a significant lower chance to benefit from NIV, supporting the existence of an intrinsic genomic-detectable resistance. Further analyses are ongoing, including a comprehensive transcriptome analysis.Legal entity responsible for the studyEmilio Bria.FundingUniversity of Verona.DisclosureS. Pilotto: Honoraria (self): AstraZeneca, BMS, Roche, MSD, Boeringher Ingelheim; Research grant / Funding (self): AIRC ; Travel / Accommodation / Expenses: BMS, Roche, AstraZeneca, Boeringher Ingelheim. M. Milella: Honoraria (self): Pfizer, EUSA Pharma, AstraZeneca. E. Bria: ...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
465PA phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
ConclusionsThrough all doses tested thus far, VT1021 has been shown to be safe for patients and induces expression of Tsp-1.Clinical trial identificationNCT03364400 December 6, 2017.Legal entity responsible for the studyVigeo Therapeutics, Inc.FundingVigeo Therapeutics, Inc.DisclosureS. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Therapeutics, Inc. K. Kerstein: Full / Part-time employment: Vigeo Therapeutics, Inc. G. Berk: Advisory / Consultancy: Vigeo Therapeutics, Inc. M.J. Cieslewicz: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Th...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
244PImmune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
ConclusionsIn HR+/HER2- early BC, non-luminal subtypes show higher TIL levels and a more pro-inflammatory anti-tumour immune infiltrate composition. This immune heterogeneity across intrinsic subtypes should be considered when analysing the complex prognostic role of TILs in HR+/HER2- early BC.Clinical trial identificationNCT00422903.Legal entity responsible for the studyUniversity of Padua.FundingGlaxoSmithKline funded the clinical trial (LETLOB) including gene-expression analysis; DOR grants 1721185/17 and 1830512/18 from the University of Padua.DisclosureM.V. Dieci: Advisory / Consultancy: EliLilly; Advisory / Consultan...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1137PIntegrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)
ConclusionsThe integrated clinical safety data indicated that RM-1929 PIT treatment had a favorable safety profile with no unexpected safety concerns.Clinical trial identificationNCT02422979.Legal entity responsible for the studyRakuten Medical, Inc.FundingRakuten Medical, Inc.DisclosureJ.M. Johnson: Advisory / Consultancy: Foundation Medicine; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Merck; Research grant / Funding (institution): AstraZeneca. J.M. Curry: Research grant / Funding (institution): AstraZeneca. S.T. Kochuparambil: Shareholder / Stockholder / Stock options, Full / Par...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
245PFrequency of germline mutations in women ’s cancer susceptibility genes in a large cohort of Chinese breast cancer patients
ConclusionsOur study derived the prevalence of P/LP germline mutation in 524 Chinese BC patients and 11% were found to have a germline mutation. We explored the characteristics of tumor somatic mutations in germline mutations carriers, which provided a better understanding of patients with germline mutations.Legal entity responsible for the studyNing Liao.FundingNational Natural Science Foundation of China (Grant No. 81602645), Guangdong Provincial Natural Science Foundation (Grant No. 2016A030313768).DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1585PDNA damage repair deficiency is associated with early resistance to crizotinib: Whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
ConclusionsThus, DDR deficiency may contribute to the early resistance to crizotinib in ALK-fusion patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
466PInterim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours
ConclusionsSL-801 reversibly binds XPO1, a clinically validated target in oncology. To date 27% of heavily pre-treated patients have achieved SD as best response. Enrollment and dose escalation continue.Clinical trial identificationNCT02667873.Legal entity responsible for the studyStemline Therapeutics.FundingStemline Therapeutics.DisclosureJ. Wang: Speaker Bureau / Expert testimony: AstraZeneca. E. Chiorean: Research grant / Funding (institution): Boehringer-Ingelheim, Merck, BMS, Lilly, Stemline, Ignyta/Roche, Incyte, Halozyme; Advisory / Consultancy: AstraZeneca, Array, Ipsen, Eisai, Halozyme, Seattle Genetics, Vicus, F...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
10PDevelopment of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumour treatment
ConclusionsThe cytotoxicity assay showed that the VEGFR2-overexpressed FS293 cells were apparently killed by VEGFR2-CART cells. The antitumor effects of the VEGFR2-CART cells have been proved in a murine tumor model, suggesting that targeting VEGFR2 with CART cells can be a novel strategy in cancer immunotherapy.Legal entity responsible for the studyDevelopment Center for Biotechnology.FundingThe government of the Republic of China (Taiwan).DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
246PTriple blinded prospective study assessing the impact of genomics & amp; artificial intelligence Watson for oncology (WFO) on MDT ’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma
ConclusionsTumor board decision can be more scientific& evidence based with the help of genomics& a learnt colleague in the form of Watson for Oncology. Even though the clinical experience is the important determinant of adjuvant therapy, genomic test with artificial intelligence, which includes the scientific evidence, will guide in decision making. Long term follow up is needed for the validation in our clinical setting.Legal entity responsible for the studyManipal Hospital Ethical Committee.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1138PFirst-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
ConclusionsICI given as second line treatment were associated with similar OS but significant prolonged duration of response. We showed a trend to better OS in the cohort of pts who received ICI in second line setting (22 months).Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
247PPrognostic significance of progesterone receptor levels in luminal-like Her2- early breast cancer patients. A retrospective single cancer center analysis
ConclusionsOur study revealed different outcomes among patients with early BC according to different PR expression levels. Noteworthy, in patients with Ki67 ≥20%, low PR expression levels (<20%) could be considered as a prognostic marker suggesting to re-evaluate PR status as a potential therapeutic guide in ER+/Her2- early BC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureA. Diana: Travel / Accommodation / Expenses: Ipsen, Novartis, Pharmamar, Italfarmaco. F. Carlino: Travel / Accommodation / Expenses: Italfarmaco, Gentili. E. Franzese: Travel / Accommodation / Expense...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1586TiPPhase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK) −positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
AbstractBackgroundThe second-generation ALK tyrosine kinase inhibitor (TKI) ALC has demonstrated efficacy and acceptable safety in ALK+ NSCLC pts who have progressed on CRZ. However, resistance to ALC eventually develops, with secondary resistance mutations detected in approximately 50% of pts and a median progression-free survival (PFS)<1 year. BRG is a next-generation ALK TKI designed to have potent and broad activity against ALK mutants. Post-CRZ, BRG demonstrated high systemic and central nervous system (CNS) objective response rates (ORRs) and the longest reported median PFS of any ALK inhibitor in this setting (16...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
467PPhase I trial of fruquintinib in patients with advanced solid tumors: Results of the dose escalation phase
ConclusionsFruquintinib is generally well-tolerated in heavily pretreated patients, with the safety profile consistent with that of other anti-angiogenic tyrosine kinase inhibitors. The RP2D in US pts is 5 mg qd (3/1), which is also the approved dose in China. Preliminary anticancer activity was evident in these pts with advanced solid tumors. The dose expansion phase of the study is ongoing. Further investigation of fruquintinib in pts with mCRC is planned.1 JAMA 2018; 319:2486.Clinical trial identificationNCT03251378.Editorial acknowledgementHoang-Lan Nguyen, PhD, Hutchison MediPharma (US), Inc.Legal entity responsibl...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
11PTriple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells
ConclusionsThese results suggest a strategy to potentially overcome immunotherapy resistance in CMS4-like tumors and to improve the efficacy of MEK inhibition by co-treatment with other agents providing an additional therapeutic strategy via modulation of host immune responses.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
